Expert panel sets protein, fluid and fiber targets for people on GLP-1 drugs
A new expert consensus sets protein, fluid and fiber targets for people on GLP-1-based drugs, aiming to limit muscle and bone loss when food intake drops.
A panel of 13 endocrinologists and diabetologists based in India has published a consensus statement setting nutrition targets for people who take GLP-1-based medications for obesity or type 2 diabetes. The recommendations cover protein, fluid and fiber intake, meal timing and how fast to eat [1].
The document, titled "Nutritional considerations for glucagon-like peptide-based therapies: An Asian Indian consensus recommendation," appears in Obesity Pillars, the journal of the Obesity Medicine Association, as Volume 19, article 100296 [1]. It uses the term glucagon-like peptide-based therapies, or GBTs, for both GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy, Rybelsus) and dual GIP and GLP-1 receptor agonists such as tirzepatide (Mounjaro, Zepbound) [1].
The targets are: protein at 20 to 30 percent of energy intake, progressing to 1.2 to 1.5 grams per kilogram of body weight per day or higher; fluid above 2 liters a day; and fiber at 20 to 30 grams a day, increased gradually and drawn from a mix of soluble and insoluble sources. The panel also recommended four to five small eating occasions a day rather than large portions, eating slowly, and avoiding large evening meals [1].
The stated reason is that GBTs commonly cause gastrointestinal side effects and change dietary intake. The panel says this can lead to nutrient deficiencies and to loss of muscle mass and bone density [1]. It notes that Asian Indians have a high prevalence of sarcopenia, the loss of muscle mass with age [1], which is why the guidance was framed around that population's dietary patterns.
The statement came out of a literature review followed by a modified Delphi process involving 13 experts. Of 44 statements, including 11 sub-statements, 43 reached high or moderate consensus [1].
Beyond the numbers, the panel emphasizes early nutritional assessment and monitoring of metabolic outcomes; a tailored, balanced diet with complex carbohydrates, high-quality protein, good-quality fat and micronutrients; adequate hydration; calorie-controlled meal replacement including diabetes-specific nutritional formulations; sustainable lifestyle practices; and resistance exercise [1]. It adds that after GBTs are discontinued, sustained nutritional support may help prevent metabolic rebound [1].
Whether these specific targets will be adopted in the United States has not been reported. No US obesity or diabetes organization is named in the paper as endorsing or adapting the recommendations, and no timeline for a US version has been disclosed [1]. The document is expert consensus, not a randomized trial, and the authors themselves write that the effectiveness and safety of GBTs, along with emerging nutrient-stimulating hormone-based therapies, should be evaluated in long-term follow-up studies [1].
Why it matters for patients
The panel ties GBT-related gastrointestinal side effects and reduced dietary intake to nutrient shortfalls and to loss of muscle and bone [1]. That is why it treats protein, fluids and fiber as things to plan around rather than secondary concerns, and why it pairs diet guidance with resistance exercise [1].
The fiber target is meant to be reached gradually, and the meal pattern is built around small, frequent eating occasions, both of which line up with tolerating food when nausea or early fullness is an issue. Large evening meals are specifically discouraged [1].
The numbers were written for Asian Indian patients and diets [1]. Calorie, protein and fluid needs vary with body weight, age, kidney function and other conditions, and the consensus does not give drug-by-drug or dose-by-dose instructions. It also does not spell out how these targets should change after treatment stops, beyond the general point about metabolic rebound [1].
What happens next
No US adaptation of the consensus has been announced, and no date for one has been reported [1]. The authors call for long-term follow-up studies of GBTs and of newer nutrient-stimulating hormone-based therapies, but no design or start date for such studies has been disclosed [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.